Collins R, Scrimgeour A, Yusuf S, Peto R (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopaedic

and urologic surgery. N Engl J Med 318:1162CrossRefPubMed 29. Handoll Torin 1 in vitro HH, Farrar MJ, McBirnie J et al (2002) Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev (4):CD000305 30. Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 370:949CrossRefPubMed 31. Kohrs R, Hoenemann CW, Feirer N, Durieux ME (1999) Bupivacaine inhibits whole blood coagulation in vitro. Reg Anesth Pain Med 24:326–330PubMed 32. Borg T, Modig J (1985) Potential anti-thrombotic effects of local anaesthetics due to their

inhibition of platelet aggregation. Acta Anaesthesiol Scand 29:739–742CrossRefPubMed 33. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF, Rosenquist RW, Rowlingson J, Tryloa M, Yuan CS (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28:172–197PubMed 34. Douketis JD, Dentali F (2006) Managing anticoagulant and antiplatelet MEK162 datasheet drugs in patients who are receiving neuraxial anesthesia and VS-4718 manufacturer epidural analgesia: a practical guide for clinicians. Tech Reg Anesth Pain Manag 10:46–55CrossRef 35. Vandermeulen EP, Van Aken H, Vermylen J (1994)

Anticoagulants and spinal–epidural anesthesia. Anesth Analg 79:1165–1177CrossRefPubMed 36. Nightingale SL (1998) From the food and drug administration. JAMA 279:346CrossRefPubMed”
“Throughout the past few decades, demographics are changing swiftly throughout the world. In the United States, Japan, China, and many parts of Europe, life expectancy has risen to well above 70 years [1]. As a result, there is an expected increase in the number of hip fractures in the world ID-8 and an increasing demand for treatment of fragility fractures [2]. Moreover, with an active lifestyle that many older patients used to enjoy, there is a bigger demand for a prompt and effective healing of the fractures and an early return to premorbid level. Fragility hip fracture is the most severe kind of fracture that is caused by osteoporosis. Hip fracture patients have a high mortality rate of up to 30% during the first year after their hip fracture [3]. Moreover, their ambulation and quality of life are significantly affected by the fracture as only 50% regained their prefracture functional status in terms of ambulatory ability and the need for walking aids [4].